Displaying 12 (all) recruiting clinical trials.
-
Prospective Database of Clinical Outcomes Following Cryotherapy for ablation of clinically localized prostate cancer
Primary Objective: To record the treatment results and impact on clinical parameters following of Cryotherapy for ablation of clinically localized prostate cancer. Primary outcome variables ...Phase N/A
Non-Interventional
-
A PHASE I/IB SINGLE ARM STUDY OF TWO FRACTION SBRT WITH DOMINANT LESION SIB FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER
Phase I/IB, single arm trial of Two-Fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost based on genomic classification in the ...Phase
Interventional
-
A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
This is a study testing MOMA-313, a drug that blocks a protein called DNA polymerase theta (Pol?) for prostate cancer with a genetic feature called ...
Phase
Interventional
-
A Phase 2 Open-label Study Evaluating Dosimetry Randomized Dose Optimization Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants with PSMA PET-Positive Castration-Resistant Prostate Cancer
This is a three-part study which includes biodistribution (Part 1), dose optimization (Part 2) to determine the optimal dose of Ac-225 rosopatamab tetraxetan to be ...Phase
Interventional
-
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF MR-LINAC- GUIDED RADIOTHERAPY AS SALVAGE TREATMENT AFTER EXTERNAL BEAM RADIOTHERAPY RECURRENCE (TUMORNATOR II)
This Phase 2 study is testing how using a special imaging technique called the Elekta Unity MR-linac system can be safe and effective for patients ...
Phase
Interventional
-
A Phase 3 Randomized Double-blind Placebo-controlled Study of Pasritamig (JNJ-78278343) a T-cell-redirecting Agent Targeting Human Kallikrein 2 + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for ...Phase
Interventional
-
Phase 1 Dose-Escalation Study of KTX-2001 (an NSD2 Inhibitor) Alone and in Combination with Darolutamide for Metastatic Castration-Resistant Prostate Cancer
This is a multicenter, open-label Phase 1 study in participants with metastatic castration-resistant prostate cancer (mCRPC) to investigate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and ...Phase
Interventional
-
RADA16 FOR AQUABLATION DAY CASE (RAD)
The purpose of the study is to assess if the use of PuraStat after the Aquablation surgery can reduce the chance of hematuria to allow ...Phase
Interventional
-
A Phase 2a Multicenter Dose Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).
This is a Phase 2 study testing a treatment called SYNC-T Therapy SV-102 in adult men with metastatic castration-resistant prostate cancer (mCRPC). SYNC-T Therapy SV-102 ...
Phase
Interventional
-
A Phase 3 Randomized Open-label Study of Pasritamig (JNJ-78278343) a T-cell-redirecting Agent Targeting Human Kallikrein 2 With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate CancerPhase
Interventional
